PDF(Pubmed)
Abstract：
BACKGROUND: Glucagon-like peptide-1 receptor agonists (GLP-1RAs) are a class of medications for management of diabetes and obesity. The objective of this study is to characterize the epidemiology of GLP-1RA cases reported to US poison centers.
METHODS: We analyzed cases involving a GLP-1RA reported to the National Poison Data System during 2017-2022.
RESULTS: There were 5,713 single-substance exposure cases reported to US poison centers involving a GLP-1RA. Most cases were among females (71.3%) and attributable to therapeutic errors (79.9%). More than one-fifth (22.4%) of cases were evaluated in a healthcare facility, including 0.9% admitted to a critical care unit and 4.1% admitted to a non-critical care unit. Serious medical outcomes were described in 6.2% of cases, including one fatality. The rate of cases per one million US population increased from 1.16 in 2017 to 3.49 in 2021, followed by a rapid increase of 80.9% to 6.32 in 2022. Trends for rates of serious medical outcomes and admissions to a healthcare facility showed similar patterns with 129.9% and 95.8% increases, respectively, from 2021 to 2022.
CONCLUSIONS: Most GLP-1RA cases reported to US poison centers were associated with no or minimal effects and did not require referral for medical treatment; however, a notable minority of individuals experienced a serious medical outcome or healthcare facility admission. The rate of reported cases increased during the study period, including an 80.9% increase from 2021 to 2022. Opportunities exist to improve provider and patient awareness of the adverse effects of these medications.
METHODS: We analyzed cases involving a GLP-1RA reported to the National Poison Data System during 2017-2022.
RESULTS: There were 5,713 single-substance exposure cases reported to US poison centers involving a GLP-1RA. Most cases were among females (71.3%) and attributable to therapeutic errors (79.9%). More than one-fifth (22.4%) of cases were evaluated in a healthcare facility, including 0.9% admitted to a critical care unit and 4.1% admitted to a non-critical care unit. Serious medical outcomes were described in 6.2% of cases, including one fatality. The rate of cases per one million US population increased from 1.16 in 2017 to 3.49 in 2021, followed by a rapid increase of 80.9% to 6.32 in 2022. Trends for rates of serious medical outcomes and admissions to a healthcare facility showed similar patterns with 129.9% and 95.8% increases, respectively, from 2021 to 2022.
CONCLUSIONS: Most GLP-1RA cases reported to US poison centers were associated with no or minimal effects and did not require referral for medical treatment; however, a notable minority of individuals experienced a serious medical outcome or healthcare facility admission. The rate of reported cases increased during the study period, including an 80.9% increase from 2021 to 2022. Opportunities exist to improve provider and patient awareness of the adverse effects of these medications.
摘要：
背景：胰高血糖素样肽-1受体激动剂（GLP-1RAs）是一类用于治疗糖尿病和肥胖症的药物。这项研究的目的是描述美国毒物中心报告的GLP-1RA病例的流行病学特征。
方法：我们分析了2017-2022年期间向国家毒物数据系统报告的涉及GLP-1RA的病例。
结果：向美国毒物中心报告了5,713例涉及GLP-1RA的单一物质暴露病例。大多数病例为女性（71.3％），可归因于治疗错误（79.9％）。超过五分之一(22.4%)的病例在医疗机构进行了评估，其中0.9%进入重症监护病房，4.1%进入非重症监护病房。6.2%的病例描述了严重的医疗结果，包括一人死亡。每百万美国人口的发病率从2017年的1.16例增加到2021年的3.49例，随后在2022年迅速增加了80.9%，达到6.32例。严重医疗结果和医疗机构入院率的趋势显示出类似的模式，分别增加了129.9％和95.8％，分别,从2021年到2022年。
结论：大多数向美国毒物中心报告的GLP-1RA病例没有或影响很小，不需要转诊治疗；然而，值得注意的少数人经历了严重的医疗结果或医疗机构入院。在研究期间，报告病例的比率有所增加，包括2021年至2022年增长80.9%。存在改善提供者和患者对这些药物的不利影响的认识的机会。
方法：我们分析了2017-2022年期间向国家毒物数据系统报告的涉及GLP-1RA的病例。
结果：向美国毒物中心报告了5,713例涉及GLP-1RA的单一物质暴露病例。大多数病例为女性（71.3％），可归因于治疗错误（79.9％）。超过五分之一(22.4%)的病例在医疗机构进行了评估，其中0.9%进入重症监护病房，4.1%进入非重症监护病房。6.2%的病例描述了严重的医疗结果，包括一人死亡。每百万美国人口的发病率从2017年的1.16例增加到2021年的3.49例，随后在2022年迅速增加了80.9%，达到6.32例。严重医疗结果和医疗机构入院率的趋势显示出类似的模式，分别增加了129.9％和95.8％，分别,从2021年到2022年。
结论：大多数向美国毒物中心报告的GLP-1RA病例没有或影响很小，不需要转诊治疗；然而，值得注意的少数人经历了严重的医疗结果或医疗机构入院。在研究期间，报告病例的比率有所增加，包括2021年至2022年增长80.9%。存在改善提供者和患者对这些药物的不利影响的认识的机会。
